Translocations Flashcards
AML M2 (myeloblastic with differentiation)
t(8;21) - good prognosis
AML1 gene on ch 21
ETO gene on 8q22
AML M3 (promyelocytic)
t(15;17)
PML gene on 15
RARA-alpha gene on 17
ML M4 (myelomonocytic with eosinophilia)
inv (16)(p13q22)
MYH11 and CBFb genes
AML M5 (monoblastic)
t(9;11)
Abl1 gene on 9
CML
t(9;22)
Abl1 gene on 9 fuses to BCR (“breakpoint cluster region”) on ch 22
reciprocal translocation
BCR-abl fusion protein - tyrosine kinase
ALL
t(4;11)
AF4 on 4
MLL on 11q23
Burkitt’s
t(8;14)
t(2;8)
t(8;22)
C-MYC on 8q24
IgH on 14q32
kappa on 2
lambda on 22
** caveat: some cases of Burkitt lack these translocations and some cases of DLBCL have a myc translocation
follicular lymphoma
t(14;18)
IgH on 14q32
BCL-2 on 18q21
B-lymphoblastic lymphoma
Good prognosis
- t(12;21)(p13;q22); TEL/AML1
- hyperdiploid > 50
- age 4-10
Bad prognosis
- t(9;22) (q34;q11.2); BCR/ABL
- 11q23; MLL
- t(1;19) (q23;p13.3); PBX/E2A
Marginal zone lymphoma
t(11;18)
API on 11
MLT-1 on 18
bladder cancer
aneuploidy of chromosomes 3, 7, 17 and loss of 9p21
Ewings sarcoma
- t(11;22); EWS/FLI-1
- t(21;22); EWS/ERG
- many others; EWS/other
- EWSR* gene on 22q12
- FLI-1* gene on ch 11
- ERG* gene on ch 21
DSRCT
t(11;22); EWS/WT-1
WT-1 gene (Wilms tumor protein) on ch11
trilineage IHC markers: CK/EMA, desmin/vimentin, NSE
Clear cell sarcoma
t(12;22); EWS/ATF-1, EWS/TEC
Myxoid/round cell liposarcoma
t(12;16); FUS/CHOP
- FUS* on 16p11
- CHOP (DDIT3)* on 12q13
Myxoid/round cell liposarcoma is the second most common type of liposarcoma. Predictors of an unfavorable outcome include greater than 5% round cell component (i.e. high grade), necrosis and p53 overexpression. Mitotic rate, fusion transcript and mature adipocytic differentiation are not as good at predicting an unfavorable outcome.
alveolar soft part sarcoma
t(X;17) unbalanced translocation
ASPL/TFE3
sensitive and specific
Synovial sarcoma
t(X;18); SYT/SSX1, SYT;SSX2
Alveolar Rhabdomyosarcoma
t(1;13); PAX7/FKRH
t(2;13); PAX3/FKRH
FKRH = FOXO1 = Forkhead box proteoin O1 = Forkhead in rhabdomyosarcoma; located on chromosome 13
DFSP
t(17;22); CALIA1/PDGF-BETA
Low grade fibromyxoid sarcoma
t(7;16); FUS/CREB
FUS = Fused in Sarcoma gene; on chromosome 16
**MUC4 is a new sensitive and specific marker for LGFMS vs other similar appearing soft tissue tumors!
t(9;22)(q34;q11)
CML or ALL
t(1;19)(q23;p13)
ALL
t(8;14)(q24;q11)
Burkitt lymphoma
t(8;21)(q22;q22)
AML M2
Embryonal rhabdomyosarcoma
LOH 11p15.5
(embryonal has better px than aleolar RMS)
embryonal rhabdomyosarcoma
LOH 11p15.5
infantile fibrosarcoma and congenital mesoblastic nephroma
t(12;15)
AML translocations associated with a good prognosis
t(15;17)
t(8;21)
Inv16
most common translocation seen in childhood B-ALL
t(12;21) –> TEL/AML1
Good prognosis!
cytogenetics associated with GOOD prognosis in ALL
t(12;21) –> TEL:AML1 fusion (need molecular b/c karyotype may miss)
Hyperdiploidy (>50 chromosomes)
del(9q) –> good in adults; not so good in kids
cytogenetics associated with BAD prognosis in ALL
t(9:22)
t(1;19) - no longer poor px with appropriate therapy
t(4;11) - neonatal acute mixed lineage leukemia
t(8;14) - uncommon in true ALL
hypodiploidy
complex karyotype (5 or more abnormalities)
round cell liposarcoma
t(12;22)
DDIT3(CHOP) on ch 12
EWS on ch22
well-diff/de-diff liposarcoma
Ring or giant marker/rod chromosomes derived from 12q13-15 in almost all cases
MDM2 amplification in well-differentiated liposarcoma
trisomies 8 & 20
desmoiods
embryonal rhabdo
infantile fibrosarcome
extraskeletal myxoid chrondrosarcoma
t(9;22)(q22-31;q11-12) EWS–CHN
or
t(9;17)(q22;q11) RBP56–CHN
papillary renal cell carcinoma
+7, +17, -Y
pediatric papillary renal cell carcinoma (translocation carcinoma)
TFE3 transcription factor gene (Xp11.2)
(t(X;17)(p11.2;q25) - balanced translocation of TFE3 gene at Xp11.2 and ASPL gene at 17q25; also found in alveolar soft part sarcoma, but unbalanced)
or
TFEB protein (11q12)
medullary carcinoma (kidney)
monosomy 11 (loss of INI-1)
Wilms tumor (nephroblastoma)
- ** WAGR** (Wilms, Aniridia, Genital anomalies, mental Retardation) - 11p13 aniridia gene + WT-1 gene deletion
- Denys-Drash syndrome (gonadal dysgenesis & nephropathy) - 11p13 mutation that affects DNA binding to WT-1
- Beckwith-Wiedemann syndrome (enlargement of orgna, hemihypertrophy, renal medullary cysts, adrenal cytomegaly) - 11p15.5, distal to WT-1 - possible genetic imprinting at WT-2
Rhabdoid tumor
Deletions or mutations of hSNF5 / INI1 / SMARCB1 gene at 22q11.2, which is associated with loss of INI1 nuclear staining
● Note: this alternation is also seen in renal medullary carcinoma (Mod Pathol 2008;21:647) and epithelioid sarcoma
t(11;22) - different from Ewing/PNET
mesoblastic nephroma
t(12;15) ETVt-NTRK3
* same as infantile fibrosarcoma
Hepatoblastoma
LOH 11p
assoc with Beckwith-Wiedeman and FAP
chondroid lipoma
t(11;16)(q13;p13)
MKL2-C11orf95 fusion gene
angiosarcoma secondary to radiation
8q24 chromosomal gains (MYC amplification) - found in 100% of secondary angiosarcoma but in primary angiosarcoma or in radiation-associated atypical vascular lesions or other radiation-associated sarcomas
angiomatoid fibrous histiocytoma
EWSR1-CREB1
lipoma
frequently (2/3) have 12q13-15 abnormalities
spindle cell lipoma
abnormalities of 13q14-22
decreases RB protein expression
male:female=9:1
most occur in the lower neck/upper back region
aneurysmal bone cyst
t(16;17) resulting in CDH11:USP6 fusion
Secretory breast carcinoma
t(12;15)
ETV6-NTRK3
abundant intra- and extracellular PAS-positive, diastase-resistant secretions
Despite its typical “triple negative” phenotype, in general secretory carcinoma has a favorable prognosis.
independent prognostic indicator in node negative breast cancer
S phase fraction
tumor size
tumor grade
cathepsin-D (a lysosomal acidic protease that can react against basement membranes and may play a role in tumor growth and metastatic potential)
Ki-67
mitotic index
vascular invasion
poor prognostic indicator in neuroblasoma
adenoid cystic carcinoma
t(6;9)(q22-23;p23-24)
MYB-NFIB fusion protein
mucoepidermoid carcinoma
t(11;19)(q14-21;p12-13)